ZOLINZA VORINOSTAT 伏立诺他

Vorinostat is a histone deacetylase (HDAC) inhibitor, mainly used to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL). As a prescription drug, it must be used strictly according to the doctor’s instructions. It may cause adverse reactions such as thrombocytopenia and diarrhea. It is contraindicated for patients with severe liver and kidney dysfunction or pregnancy.

Core information

Indications

It is suitable for adult patients with cutaneous T-cell lymphoma (CTCL), especially those who are ineffective or relapsed with other treatment options.
It may have a certain effect on some other blood tumors (such as peripheral T-cell lymphoma), but further research is needed to support it.
‌Mechanism of action‌

By inhibiting the HDAC enzyme, regulating gene expression, promoting tumor cell differentiation and apoptosis, and inhibiting proliferation.
Indirectly affects the tumor microenvironment and enhances the immune system’s ability to recognize cancer cells.
‌Usage and dosage‌

Oral administration, usually once a day, 400 mg each time, taken with meals to reduce gastrointestinal irritation.
The dose may be adjusted according to the patient’s tolerance, and blood routine and liver and kidney function need to be monitored regularly.
‌Common adverse reactions‌

‌Blood system‌: thrombocytopenia (about 25%), anemia, leukopenia.
‌Digestive system‌: diarrhea (52%), nausea, decreased appetite.
‌Others‌: fatigue, dry mouth, abnormal taste, and occasionally prolonged QT interval on electrocardiogram.
‌Contraindications and cautions‌

‌Contraindications‌: severe liver and kidney dysfunction, pregnancy, and allergies to ingredients.
‌Use with caution‌: patients with underlying heart disease, electrolyte disorders (such as hypokalemia/hypomagnesium), or those who are using other drugs that prolong the QT interval.
‌Precautions‌

During treatment, the platelet count needs to be monitored every 2 weeks. If it is lower than 50×10⁹/L, the medication should be discontinued.
Avoid combined use with anticoagulants and nonsteroidal anti-inflammatory drugs to prevent increased risk of bleeding.
Lactating women need to stop breastfeeding during medication.
If you experience symptoms such as persistent diarrhea, abnormal bleeding, or palpitations, you should seek medical attention immediately. This drug must be used under the guidance of an oncologist, and the patient’s underlying disease and drug interactions must be fully evaluated before treatment.